Open
| Close
| High
| Low
| Previous Close
| Daily Price Gain
|
YTD High
| YTD High Date
| YTD Low
| YTD Low Date
| YTD Price Change
| YTD Gain
|
52 Week High
| 52 Week High Date
| 52 Week Low
| 52 Week Low Date
| 52 Week Price Change
| 52 Week Gain
|
These are sample algorithmic trades based on actual market data.
Stock Symbol
| Exchange
| Company URL
| Company Phone
|
CEO
| Headquarters
| Business Address
| |
Sector
| Industry Category
| Industry Group
| CIK
|
About
BioSpecifics Technologies Corp. operates as a biopharmaceutical company, which engages in development of an injectable collagenase for multiple indications. Its product includes XIAFLEX, is an injectable collagenase enzyme, which is used for the treatment of Dupuytren's contracture in adults with a palpable cord in the palm. The company was founded in 1990 and is headquartered in Lynbrook, NY. | |||
Description
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York. |